Conv. Plasma
Nigella Sativa
Peg.. Lambda

All vitamin D studies
Meta analysis
Home COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 5% Improvement Relative Risk Vitamin D for COVID-19  Guldemir et al.  Prophylaxis Is prophylaxis with vitamin D beneficial for COVID-19? Retrospective 477 patients in Turkey (March - September 2020) No significant difference in hospitalization Guldemir et al., Work, November 2022 Favors vitamin D Favors control

Clinical characteristics of bus drivers and field officers infected with COVID-19: A cross-sectional study from Istanbul

Guldemir et al., Work, doi:10.3233/wor-220292
Nov 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 477 COVID+ public transportation workers in Turkey, showing no significant difference in hospitalization with vitamin D use in unadjusted results.
This is the 102nd of 116 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 38 sextillion). 28 studies are RCTs, which show efficacy with p=0.0000081. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
This study includes vitamin D and vitamin C.
risk of hospitalization, 5.2% lower, RR 0.95, p = 0.89 (Fisher's exact test), treatment 19 of 81 (23.5%), control 98 of 396 (24.7%), NNT 77.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Guldemir et al., 16 Nov 2022, retrospective, Turkey, peer-reviewed, 3 authors, study period 30 March, 2020 - 23 September, 2020, dosage not specified.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Clinical characteristics of bus drivers and field officers infected with COVID-19: A cross-sectional study from Istanbul
Hilal Hizli Guldemir, Merve Kayali Sevim, Serkan Eti
Work, doi:10.3233/wor-220292
BACKGROUND: In metropolitans, where public transportation is used extensively, bus drivers are one of the occupational groups with a high risk of contracting COVID-19. OBJECTIVE: This study aimed to assess the difference between the clinical status of a group of bus drivers and field officers with COVID-19 on public transportation lines in Istanbul. METHODS: The study was conducted with 477 male volunteer participants. COVID-19 was confirmed through a positive nasopharyngeal culture sample using the real-time PCR test. Demographic information, biochemical parameters, clinical status, and the use of nutritional supplements were compared between those who recovered from COVID-19 at home or in the hospital. RESULTS: The body mass indexes (BMI) of 83.9% of individuals was above normal and 75.4% were treated for the disease at home. There were significant differences in terms of age, BMI, weight loss, smoking, use of nutritional supplements, blood glucose levels and vitamin B 12 values. However, there was no significant difference between the types of nutritional supplements used or other biochemical parameters. CONCLUSION: It was determined that those who survived the disease at home were younger and had a lower BMI. It is important for both individuals and for general public health to create healthy working environments, especially for bus drivers, who have a high risk of COVID-19 contamination and transmission due to their long exposure time.
Bilgili, Özcelik, Bilir, Alkan, Telli et al., IETT 2020 Faaliyet Raporu
Caussy, Pattou, Wallet, Simon, Chalopin, None
Charu, Zeger, Gog, Bjørnstad, Kissler et al., Human mobility and the spatial transmission of influenza in the United States. Salathé M, editor, PLOS Comput Biol, doi:10.1371/jour-nal.pcbi.1005382
Chen, Klein, Garibaldi, Li, Wu et al., Aging in COVID-19: Vulnerability, immunity and intervention, Ageing Res Rev, doi:10.1016/j.arr.2020.101205
Costa, Souza, Silva, None, Conceic
Descarrega-Reina, Hernández-Aguilera, Riu, Risk factors associated with mortality in hospitalized 536 patients with SARS-CoV-2 infection. A prospective, 537 longitudinal, unicenter study in Reus, Spain, PLoS One, doi:10.1371/journal.pone.0234452539
Deveci, Aydın, Kus, Managing Public Transport During COVID-19: An Analysis of the Impact and Preventive Response in Istanbul, J Nav Sci Eng
Duhamel, High Prevalence of Obesity in 524
Francois, Obesity in Patients Younger Than 60 Years
Fu, Wang, Yuan, Chen, Ao et al., Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and metaanalysis, J Infect, doi:10.1016/j.jinf.2020.03.041
Galmés, Serra, Palou, Current State of Evi-551 dence: Influence of Nutritional and Nutrigenetic Factors on 552 Immunity in the COVID-19 Pandemic Framework, Nutri-553 ents, doi:10.3390/nu12092738
Goldblatt, Morrison, Initial assessment of London bus driver mortality from covid-19
Hamulka, Jeruszka-Bielak, Górnicka, Drywień 545 Me, Ma, Dietary Supplements during 546 COVID-19 Outbreak. Results of Google Trends Analysis 547 Supported by PLifeCOVID-19 Online Studies, Nutri, doi:10.3390/nu13010054
Holdoway, Nutritional management of patients during and after COVID-19 illness, Nutrition, doi:10.12968/bjcn.2020.25.Sup8.S6
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Iftimie, López-Azcona, Miralles, None
Kamga, Eickemeyer, Slowing the spread of COVID-19: Review of "Social distancing" interventions deployed by public transit in the United States and Canada. Transp Policy, doi:10.1016/j.tranpol.2021.03.014
Lai, Shih, Ko, Tang, Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105924
Liam, Prevalence of obesity among adult inpatients 530 with COVID-19 in France, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(20)30160-1.532
Lighter, Phillips, Hochman, Sterling, Johnson, None
Malki-Epshtein, Mechanics, Quality, Fluid, screen modifications due to the Covid-19 pandemic
Santos, Nonato, Santana, Obesity and clin-514 ical severity in patients with COVID-19: a scoping review 515 protocol, Syst Rev, doi:10.1186/s13643-516021-01603-x
Simonnet, Chetboun, Poissy, Raverdy, None, Noulette
Tian, Hu, Lou, Chen, Kang et al., Characteristics of COVID-19 infection in Beijing, J Infect, doi:10.1016/j.jinf.2020.02.018
Wu, Chen, Cai, Xia, Zhou et al., Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, JAMA Intern Med, doi:10.1001/jamainternmed.2020.0994
Yasri, Wiwanitkit, Public Tourist Bus, Tourist Bus Driver, and COVID-19 Infection: A Note, Int J Prev Med, doi:10.4103/ijpvm.IJPVM15120
Zhao, Meng, Kumar, Wu, Huang et al., The impact of COPD and smoking history on the sever-541 ity of COVID-19: A systemic review and meta-analysis, J
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop